Several other analysts have also commented on the stock. Zacks Investment Research upgraded shares of Cempra from a sell rating to a hold rating in a research report on Tuesday, October 17th. Roth Capital lowered shares of Cempra from a buy rating to a neutral rating and dropped their target price for the company from $8.00 to $4.00 in a research report on Thursday, August 10th. Finally, Stifel Nicolaus reiterated a hold rating and issued a $4.00 target price on shares of Cempra in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $6.05.
Shares of Cempra (NASDAQ MLNT) traded up $0.05 during trading on Thursday, hitting $12.00. 83,200 shares of the company traded hands, compared to its average volume of 135,246. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.49 and a quick ratio of 11.49. Cempra has a 12-month low of $10.25 and a 12-month high of $41.00.
Cempra (NASDAQ:MLNT) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.09. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $3.58 million. Cempra had a negative net margin of 500.05% and a negative return on equity of 45.72%. The firm’s revenue was down 74.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.51) earnings per share. equities analysts anticipate that Cempra will post -4.92 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Cempra, Inc. (MLNT) Receives “Neutral” Rating from Jefferies Group LLC” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/13/cempra-inc-cemp-stock-rating-reaffirmed-by-jefferies-group-llc.html.
Cempra Company Profile
Melinta Therapeutics, Inc, formerly Cempra, Inc, is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.